Main menu

Product Pipeline

Product Pipeline

Our Medicines in Development

Pfizer is prioritizing its research and development efforts in areas with the greatest scientific and commercial promise: immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain, and vaccines. Through major research efforts across multiple modalities — including small molecules, biologics and vaccines — Pfizer is developing the medical solutions that will matter most to the people we serve. Specialized efforts in biosimilars as well as rare diseases also illustrate our dedication to developing and delivering innovative medicines and vaccines that will benefit patients around the world.

Key Programs in Registration / Phase 3

  • Xeljanz® (tofacitinib) – Ulcerative Colitis, Psoriasis (oral), Psoriatic Arthritis
  • Palbociclib: Advanced Breast Cancer (1st Line & Recurrent), High Risk Early Breast Cancer
  • Prophylactic Vaccine for Meningococcal Serogroup B
  • PCSK9 Inhibitor (bococizumab/RN316): Hyperlipidemia
  • Ertugliflozin: Type 2 Diabetes (in collaboration w/ Merck)
  • Trastuzumab: Breast Cancer

Key Programs in Phase 2

  • Xeljanz® (tofacitinib): Crohn’s disease, Ankylosing Spondylitis, Psoriasis (topical), Atopic Dermatitis
  • Anti-IL-6 Antibody: Crohn’s disease, Lupus
  • Anti MadCAM: Crohn’s Disease, Ulcerative Colitis
  • PDE5 Inhibitor: Diabetic Nephropathy
  • CCR2/5 Antagonist: Diabetic Nephropathy
  • Inlyta®: Hepatocellular Carcinoma
  • PI3K/mTOR Inhibitor: Colorectal Cancer
  • ALK-1 Inhibitor mAb: Hepatocellular Carcinoma
  • SMO Inhibitor: Acute Myeloid Leukemia
  • Prophylactic Vaccine for Staphylococcus Aureus
  • GMI-1070 (Rivipansel): Sickle Cell Disease
  • PDE10 Inhibitor: Huntington's Disease, Adjunctive Treatment for Schizophrenia